IDEXX Laboratories, Inc. (IDXX) Earnings

IDEXX Laboratories, Inc.

IDXX · NASDAQ-GS

Sep 2026upcoming

Next quarter

Consensus is $3.77 EPS for Sep 2026 across 6 estimates, ranging $3.70 to $3.86.

IDXX Jun 2026

Reported Aug 4, 2026

Beat 8.10%

EPS estimate: $3.95
EPS actual: $4.27
Revenue estimate: —
Revenue actual: —
1-day move: —

Call highlights have not been generated for this quarter.

Symbol: IDXX
Type: Stock
Sector: Health Care
Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances
Country: North America
Exchange: NASDAQ-GS

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions-to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500 Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.

Key Issues

Bullish view

Management raised its full-year EPS outlook after a second-quarter earnings beat, suggesting operating performance is running ahead of expectations.

Bearish view

The company narrowed its full-year revenue outlook even while lifting EPS guidance, indicating that the earnings improvement may rely more on margins than on a broader revenue outlook.

Analyst Consensus

See all

Buy

13 analysts

$586

Current

—

Low

$745

Average

—

High

Average target implies +27.11% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share ofTAK · NYSE$16.59